{"id":"W4414927188","doi":"10.1007/s13555-025-01557-1","title":"Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dermatrials Research","funders":"Manchester Biomedical Research Centre; Allergan; LEO Pharma; National Institute for Health and Care Research; Incyte; Sun Pharma; Regeneron Pharmaceuticals; UCB; Celgene; Biogen; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Clinical trial; Post-hoc analysis; Psoriasis; Post hoc; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001185644,0.0002389948,0.001653208,0.0006679774,0.000105789,0.000008537461,0.0001926987,0.000622215,0.0003097728],"category_scores_gemma":[0.0002411102,0.000188595,0.0004433206,0.0007846897,0.0003270195,0.00005450143,0.00003363982,0.0001996674,0.00002243424],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001117671,"about_ca_system_score_gemma":0.00006622292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008156445,"about_ca_topic_score_gemma":0.00005766682,"domain_scores_codex":[0.9957644,0.002339615,0.001158721,0.0004142167,0.00002652973,0.0002965292],"domain_scores_gemma":[0.9966683,0.002600379,0.0003117145,0.0003349718,0.00005742005,0.0000271563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01439229,0.00484932,0.1335522,0.00002225099,0.02088999,0.00004629478,0.0007175981,0.000001163369,0.04617393,0.002627575,0.004314039,0.7724133],"study_design_scores_gemma":[0.2022228,0.002929174,0.3909163,0.0001234926,0.01218902,0.000132136,0.0009982203,0.00009582216,0.2420119,0.001189961,0.1458328,0.001358327],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9496874,0.04809548,0.00006468329,0.0007051978,0.0006870462,0.0003221992,0.0001892511,0.00003363338,0.0002150904],"genre_scores_gemma":[0.9863502,0.0123346,0.00002590412,0.0004830742,0.00001168614,0.00003748942,0.0005346835,0.000008600781,0.0002137087],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.771055,"threshold_uncertainty_score":0.769068,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04833259873561692,"score_gpt":0.3833636814334019,"score_spread":0.335031082697785,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}